Vactosertib

Non Chimik:

N-((4-([1,2,4]triazolo[1,5-a]piridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl )-2-fluoroanilin

Kòd SMILES:

FC1=CC=CC=C1NCC2=NC(C3=CN4C(C=C3)=NC=N4)=C(C5=NC(C)=CC=C5)N2

Kòd InChi:

InChI=1S/C22H18FN7/c1-14-5-4-8-18(27-14)22-21(15-9-10-20-25-13-26-30(20)12- 15)28-19(29-22)11-24-17-7-3-2-6-16(17)23/h2-10,12-13,24H,11H2,1H3,(H,28,29 )

InChi kle:

FJCDSQATIJKQKA-UHFFFAOYSA-N

Mot:

Vactosertib, EW-7197, EW7197, EW 7197, 1352608-82-2

Solibilite:Soluble nan DMSO

Depo:0 - 4 ° C pou kout tèm (jou a semèn), oswa -20 ° C pou tèm long (mwa)

Deskripsyon:

Vactosertib, ke yo rele tou EW-7197 se yon inibitè ALK5 ki pisan. EW-7197 te montre pisan aktivite anti-metastatik nan vivo, ki endike potansyèl li pou itilize kòm yon terapi anti-kansè. EW-7197 inibit siyal TGF-β/Smad. EW-7197 abroge TGF-β1-induit migrasyon selil timè ak envazyon. EW-7197 inibit metastaz kansè nan tete nan poumon.EW-7197 pwolonje lavi sourit BALB/c 4T1 atravè anpèchman EMT. EW-7197 inibit metastaz ak amelyore aktivite lenfosit T sitotoksik (CTLs) nan sourit 4T1 orthotopic grefon.

Sib: ALK